For providers
How it compares

An industry standard for breast cancer testing

The Oncotype DX Breast Recurrence Score® test delivers critical genomic information unlike any other genomic test, offering personalized insights to help guide treatment decisions.1-4
A technician's hand working with a lab sample.

Included in major international breast cancer treatment guidelines

The 21-gene assay (Oncotype DX®) is included in leading international oncology guidelines, including those from the National Comprehensive Cancer Network® (NCCN®), the American Society of Clinical Oncology, and the European Society for Medical Oncology (ESMO).5-11*

*National Comprehensive Cancer Network and NCCN are registered trademarks of the National Comprehensive Cancer Network.

  • The only genomic assay with the highest recommendation in 5 major international guidelines for risk assessment in patients with early-stage breast cancer5-9
  • Included as a recommendation in 2 additional guidelines10,11

What sets our test apart

A patient sitting on an exam table talking to her doctor.

It is predictive and prognostic

The Oncotype DX Breast Recurrence Score test is the only test that offers both prognostic and predictive results you can count on for your patients with early-stage invasive breast cancer.3-5,12,13

It is comprehensive

The Oncotype DX Breast Recurrence Score test goes beyond clinicopathological factors, using genomic insights to provide personalized information about the estimated risk of distant recurrence and potential benefit of adjuvant chemotherapy for each unique patient.14-17

Backed by a solid body of clinical evidence

The Oncotype DX Breast Recurrence Score test has been validated across multiple peer-reviewed studies in top-tier journals spanning over 20 years.3,4,12-17
A doctor seated at a desk looking at his laptop.

Ordering a test for your patients is fast and easy

Order tests, access results, and receive updates through our Provider Hub.

Have questions?

Call us at 1 866-662-6897.